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Abstract
Background: Adoptive transfer of genetically engineered autologous T-cells is becoming a successful therapy for
cancer. The avidity of the engineered T-cells is of crucial importance for therapy success. We have in the past
cloned a T-cell receptor (TCR) that recognizes an HLA-A2 (MHC class I)-restricted peptide from the prostate and
breast cancer- associated antigen TARP. Herein we perform a side-by-side comparison of the TARP-specific TCR
(TARP-TCR) with a newly cloned TCR specific for an HLA-A2-restricted peptide from the cytomegalovirus (CMV)
pp65 antigen.
Results: Both CD8+ T-cells and CD4+ T-cells transduced with the HLA-A2-restricted TARP-TCR could readily be
detected by multimer analysis, indicating that the binding is rather strong, since binding occured also without the
CD8 co-receptor of HLA-A2. Not surprisingly, the TARP-TCR, which is directed against a self-antigen, had weaker
binding to the HLA-A2/peptide complex than the CMV pp65-specific TCR (pp65-TCR), which is directed against a
viral epitope. Higher peptide concentrations were needed to achieve efficient cytokine release and killing of target
cells when the TARP-TCR was used. We further introduce the LigandTracer technology to study cell-cell interactions
in real time by evaluating the interaction between TCR-engineered T-cells and peptide-pulsed cancer cells. We were
able to successfully detect TCR-engineered T-cell binding kinetics to the target cells. We also used the xCELLigence
technology to analyzed cell growth of target cells to assess the killing potency of the TCR-engineered T-cells. T-cells
transduced with the pp65 - TCR exhibited more pronounced cytotoxicity, being able to kill their targets at both
lower effector to target ratios and lower peptide concentrations.
Conclusion: The combination of binding assay with functional assays yields data suggesting that TARP-TCR-
engineered T-cells bind to their target, but need more antigen stimulation compared to the pp65-TCR to achieve
full effector response. Nonetheless, we believe that the TARP-TCR is an attractive candidate for immunotherapy
development for prostate and/or breast cancer.
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Background
Cancer immunotherapy is becoming a cornerstone in
the clinical care of cancer patients due to the break-
through of immune checkpoint blockade antibodies [1].
Adoptive transfer of ex vivo-engineered autologous T-
cells has also been successful, especially when T-cells are
engineered with a chimeric antigen receptor (CAR)
against CD19 and used for treatment of B cell malignan-
cies [2–5]. A CAR molecule has an extracellular single
chain antibody fragment for tumor antigen recognition
and intracellular signaling domains from the T-cell re-
ceptor (TCR) CD3z chain and co-stimulatory molecules.
CAR T-cells provide the advantage of major histocom-
patibility complex (MHC)-independent binding to
tumor-associated antigens on the surface of tumor cells.
However, the requirement of surface expression of the
antigen limits the available targets making it difficult to
identify new and specific CAR targets. Additionally,
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CAR T-cells do not require very high antigen expression
to execute their effector function [6–8], which may be a
drawback when targeting antigens that are over-
expressed but not restricted to tumor cells.
T-cells engineered with a novel TCR can target anti-
genic peptides presented by MHC molecules on the sur-
face of tumor cells. This means that also intracellular
mutated neoepitopes can be recognized and targeted. As
the T-cell naturally uses the TCR for binding, the affinity
of the interaction of the introduced TCR would be in
the physiological range in which the TCR normally
binds. That would at least partly avoid toxicity to normal
cells with low expression level of the targeted antigen.
As tumor-associated antigens are processed a variety of
tumor-associated peptides is available for targeting with
TCR-engineered T-cells. TCR-engineered T-cells are
now starting to show progress for solid tumors [2]. With
novel techniques involving exon and RNA sequencing
for identification of mutated neoepitopes, TCR T-cell
therapy can be developed on an individual basis [9].
The apparent strength of the interaction between the
TCR and MHC/peptide complex is dependent on the af-
finity, avidity and functional avidity of the TCR for its
target. Measuring the dissociation rate or the half-life of
a single TCR-MHC/peptide interaction reflects the resi-
dence time of the TCR/MHC interaction. Such biochem-
ical measurement is technically challenging and often
does not reflect the kinetics of multiple receptor/ligand
interactions (avidity), which are needed for the activation
of the T-cell. Higher avidity T-cells are found to be more
rapidly activated and exert a better cytotoxic function
[10], though that is still debated, reviewed in [11]. How-
ever, high avidity T-cells may have a lower sensitivity to
their ligand. Treating cancer patients with adoptive T-
cell therapy that result in targeting normal tissue and se-
vere side effects. In addition, over-stimulated T-cells
are short-lived and prone to apoptosis upon antigen
engagement. Because TCR-MHC/peptide binding is
strengthened by co-receptor binding to MHC, co-
receptor expression may affect the subsequent ac-
tivation of the T-cells. To measure how well T-cells
respond to antigen-specific stimulation, the term
functional avidity is used. Functional avidity is directly
related to the ability of T-cells to adhere to and kill
cells expressing the target antigen.
Many reports indicate that virus-specific T-cells are of
high affinity (often in the nM range), in contrast to T-
cells directed towards the body’s own proteins that are
of low affinity due to deletion of high affinity clones in
the thymus to avoid targeting self-tissue and auto-
immunity [12]. We have cloned two TCRs, one TCR rec-
ognizes an HLA-A2-restricted peptides from the
prostate and breast cancer-associated antigen TARP [13]
and in this paper one TCR recognizing an HLA-A2-
restricted peptide from the cytomegalovirus (CMV)
pp65 antigen. These TCRs are compared side-by-side.
As TARP is an antigen highly expressed in prostate can-
cer cells it has a potential to be used in the clinics.
Therefore, characterization of its affinity, avidity and
function as compared to a virus-directed TCR would
provide basic information for its effectiveness and safety.
Methods
Cells and cell lines
Target cells: Mel526 cells (HLA-A2+) was cultured in
Dulbecco’s Modified Eagle Medium (DMEM), supple-
mented with 10 % fetal bovine serum (FBS), 1 % penicil-
lin/streptomycin (PEST) and 1 mM sodium pyruvate. T2
cells (HLA-A2+) were grown in RPMI-1640 containing
10 % FBS and 1 % PEST. Producer cells: HEK-293 T-cells
was cultured in DMEM, 10 % FBS, 1 % PEST and
500 μg/ml geneticin (used only during culturing but not
during virus production). Peripheral blood mononuclear
cells (PBMCs) from buffy coat blood of healthy volun-
teers (unidentified; bought from the Uppsala University
Hospital blood center) were isolated using Ficoll Paque
(GE Healthcare, Uppsala, Sweden). PBMCs were cul-
tured in RPMI-1640 supplemented with 10 % human
AB-serum (own production), 100 IU/ml interleukin (IL)-
2 (Proleukin, Novartis, Basel, Switzerland), 2 mM L-glu-
tamine, and 10 mM HEPES. The cell culture reagents
were purchased from Life Technologies (Carlsbad, CA).
Peptides, peptide pulsing and multimers
The HLA-A2-restricted peptides: TARP(P5L)4–13 (amino
acid sequence FLPSPLFFFL) [14], CMV pp65495–503
(NLVPMVATV) [15] and as negative control VMAT-
131–39 (LLLDNMLFT) were synthesized to purity above
95 % (Genscript, Piscataway Township, NJ). Target cells
were pulsed for 2 h with peptide at concentrations of
50 μM, 10 μM, 1 μM, 100 nM, 10 nM, 1 nM, 100 pM
and 10 pM (only the highest concentration was used for
the VMAT-131–39 control peptides). Phycoerythrin (PE)-
conjugated TARP(P5L)4–13/HLA-A*0201 dextramer was
purchased from Immudex (Copenhagen, Denmark) and
PE-conjugated pp65495–503/HLA-A*0201 tetramer was
purchased from MBL International (Woburn, MA).
TCR cloning and viral vector construction
We have previously reported cloning of the TCR recog-
nizing the TARP4–13/HLA-A2 complex. [13] The TCR
recognizing the CMV pp65495–503/HLA-A2 complex was
cloned using the same approach. In brief, PBMCs, iso-
lated from a HLA-A2 positive, CMV-seropositive donor,
were stained with the pp65495–503 tetramer and
tetramer-positive T-cells were isolated using magnetic
beads. T-cells were cloned at 0.6 cells/well in 96-well
plates and expanded with IL-2 and irradiated feeder cells
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before testing for peptide reactivity. The TCR chains of
ten reactive clones were sequenced and found to contain
one unique TCR-α chain and one unique TCR-β chain.
A recombinant sequence with the identified TCR α
chain linked to the β chain was cloned into a lentiviral
vector under the Spleen Focus-Forming Virus (SFFV)
promoter. The α and β chains were separated by a 2A
self-cleaving peptide sequence from Thosea Asigna Virus
(T2A). Mouse constant domains of TCR α and β were
used to improve the pairing between the chains of the
introduced TCR chains and avoid mispairing with en-
dogenous TCR α and β chains. Vesicular stomatitis virus
(VSV)-G pseudotyped lentiviral particles were produced
in HEK 293-T-cells and concentrated by ultracentrifuga-
tion as described previously [13].
T-cell activation, transduction and sorting of TCR-
transduced T-cells
T-cells in a pool of freshly isolated PBMCs were acti-
vated for 48 h using 100 ng/ml OKT3 antibody (Nordic
Biosite, Täby, Sweden) and 100 IU/ml IL-2. One million
activated PBMCs were then transduced for 4 h with
50 μl concentrated lentivirus, encoding the pp65-TCR or
TARP-TCR as described previously [13]. After transduc-
tion the cells were plated in 24-well plates, rested over-
night and re-transduced 24 h later. The transduced cells
were tested for transduction efficiency using multimers
and flow cytometry analysis 7 days after transduction.
To purify TCR-engineered T-cells, the transduced cells
were stained with PE-conjugated pp65495–503/HLA-
A*0201 tetramer or PE-conjugated TARP(P5L)4–13/
HLA-A*0201 dextramer for 30 min at 4 °C. Anti-PE
magnetic beads (Miltenyi Biotec, Bergisch Gladbach,
Germany) were then used to separate the PE-labeled T-
cells according to manufacturer’s instructions. The pur-
ity was estimated by flow cytometry (FACSCanto II BD
Biosciences, Franklin Lakes, NJ) using PE-conjugated
tetramer/dextramer and antibodies (Biolegend, San
Diego, CA) against the following markers: CD3 conju-
gated with allophycocyanin (APC) or Pacific Blue, CD8
conjugated with fluorescein isothiocyanate (FITC), CD4
conjugated with APC. The results were analyzed using
FACS Diva 8 and Flow Jo software (Ashland, OR). The
sorted TCR-engineered T-cells were then expanded
using a rapid expansion protocol as described earlier
[13]. The expanded T-cells then reassessed by flow cy-
tometry and were in all cases found to be > 90 % multi-
mer positive.
Ligand Tracer® measurement of T-cell binding to target cells
One million mel526 target cells in 2 ml of culture medium
were let to adhere overnight to a tilted 10-cm Petri dish.
The target cells were then pulsed with peptides as de-
scribed above. The Petri dish was then inserted on the
tilted rotating platform of the Ligand Tracer® instrument
(Ridgeway Instruments AB, Uppsala, Sweden) and back-
ground measurement of fluorescence was done in real
time during rotation (1 rpm) for 30 min.
Transduced and expanded TCR-engineered T-cells were
labeled with Carboxyfluorescein succinimidyl ester (CFSE)
according to manufacturer’s instructions (Thermo Fisher,
Uppsala, Sweden) and then washed thoroughly with
serum-containing medium. CFSE-labeled TCR-engineered
T-cells (1.5 × 105 cells) were then added to the Petri dish
with peptide-pulsed target cells. Rotation started again
and T-cell binding (association) to the target cells was
measured in real time through detection of fluorescent
signal from the target cells (T-cell binding) with subtrac-
tion of the fluorescent signal from the opposite side of the
Petri dish without target cells. After 90 min another 3 ×
105 T-cells were added and the measurement continued.
ELISA and killing assays
For specific TCR activation experiments, the transduced
T-cells were co-cultured with target cells pulsed with rele-
vant peptide and control peptide as described above. To
detect IFN-γ secretion, 1 × 105 peptide-pulsed T2 target
cells were co-cultured overnight with TCR-engineered T-
cells (effector to target ratio 1:1). Supernatants were col-
lected and IFN-γ was measured using ELISA (Mabtech,
Nacka Strand, Sweden). For killing assays, 1 × 105 peptide-
pulsed luciferase-expressing mel526 target cells were co-
cultured with TCR-engineered T-cells at 1:1 ratio (effector
to target ratio 1:1) or target cells were pulsed with 10 μM
peptide and mixed with effector T-cells at different
effector to target ratios (10:1, 5:1, 1:1, 1:5 and 1:10). The
results in terms of luciferase activity were analyzed after
72 h using Steady-Glo Luciferase Assay System (Promega,
Madison, WI) according to manufacturer’s instructions.
For the xCELLigence cell growth assay 2 × 104 mel526 tar-
get cells were plated in an E-Plate View (ACEA Biosci-
ences, San Diego, CA). Cell growth was measured
overnight using the xCELLigence RCPA DP Instrument
(ACEA Biosciences). The next day, the target cells on the
E-plate View were pulsed for 2 h with TARP(P5L)4–13 or
pp65495–503 peptide at 10 μM, 100nM or 1nM. The ef-
fector T-cells were then added to the target cells (approxi-
mately 26 h after plating of the target cells) in 1:1, 5:1 and
10:1 effector to target ratios and the killing of the target
cells was continuously measured for an additional 48 h.
Results
T-cells can efficiently be engineered to express TCRs
recognizing HLA-A2-restricted TARP or CMV pp65
peptides
The TCR against the HLA-A2/pp65495–503 complex was
cloned into a lentiviral vector and compared with a
lentiviral vector having the TCR against the HLA-A2/
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TARP4–13 complex (Fig. 1). Peripheral blood mono-
nuclear cells (PBMCs) were isolated from buffy coat
blood of healthy donor. T-cells in the PBMC pool were
activated and then transduced with the TCR-encoding
lentiviral vectors. The TCR-engineered T-cells then
served as a model system to understand the complex in-
teractions between MHC/peptide and TCR and to com-
pare their ability to bind and respond to target cells.
Several groups have used multimer technology to as-
sess the binding strength of a certain TCR against an
MHC/peptide complex. [16–18] To determine how well
the CMV pp65-specific TCR (pp65-TCR) and TARP-
specific TCR (TARP-TCR) bind to their corresponding
HLA-A2/peptide complex, T-cells transduced with the
TCRs were analyzed and compared using multimers/
flow cytometry and the mean fluorescent intensity (MFI)
was used as a measure of their binding strength. Exam-
ples from representative experiments showing multimer
binding seven days after transduction (Fig. 2a), followed
by subsequent multimer/PE-bead sorting (Fig. 2b) and
after another fourteen days of rapid expansion (Fig. 2c).
The average percentage of multimer positive CD4+ T-
cells and CD8+ T-cells prepared from 3 donors is shown
in Fig. 2d. More T-cells were transduced with the pp65
TCR than with the TARP-TCR and we found more CD4
+ T-cells than CD8+ T-cells for both TCR transduction.
A higher MFI was also observed for pp65-TCR T-cells
than for TARP-TCR T-cells (Fig. 2e), indicating stronger
binding, both for TCR-engineered CD8+ and CD4+ T-
cells. The binding of the TCR to MHC/peptide complex
is influenced by many factors, one of which is the pres-
ence of co-receptor (CD8 or CD4) binding to the con-
served part of MHC to stabilize the complex. [19–21]
The pp65-TCR and TARP-TCR are binding peptides
presented by HLA-A2 (MHC class I) for which CD8 is
the co-receptor. Higher MFI for CD8+ T-cells than CD4
+ T-cells probably reflects the influence of the CD8 co-
receptor for the MHC class I restricted TCRs. High-
affinity TCRs are less dependent on co-receptor binding
than low-affinity TCRs. Multimer positivity on TCR-
engineered CD4+ T-cells therefore indicates a rather
high TCR affinity also for the TARP-TCR.
TCR-engineered T-cell binding to target cells can be stud-
ied in real time using the Ligand Tracer Technology
To understand the kinetics of T-cell binding to target
cells, LigandTracer® technology was used (Fig. 3a). A
short description of the protocol is outlined in Fig. 3b.
Target cells, in our case the HLA-A2+ Mel526 cells, are
adhered to one side of a tilted Petri dish in an incubator
over night and in the morning pulsed with peptide, in
our case HLA-A2 restricted TARP4–13 or pp65495–503.
The Petri dish with pulsed and washed cells is then
inserted to the round tilted platform of LigandTracer.
As the dish rotates, fluorescent detectors at the top of
the instrument (where essentially no medium is present
because of the tilting) measure the fluorescent signals.
When fluorescently CFSE-labeled effector T-cells are
added to the medium, a fluorescence signal is detected
as they bind to the target cells. Since the target cells are
only plated at one side of the rotating Petri dish, TCR
binding to MHC/peptide is measured as the difference
in fluorescence signal between the signal detected at the
target cells and the background signal on the opposite
side of the dish (no target cells). The peptide concentra-
tions that were optimal for activation were determined by
classical functional assays described below. We pulsed
mel526 target cells with 10 μM TARP4–13 or
10 nm pp65495–503 peptide. At the beginning of the experi-
ment 1.5 × 105 T-cells were added. The initial binding was
linear, and the measurement was conducted for 90 min
(Fig. 3c, f ). At 90 min, 3 times more T-cells (4.5 × 105)
were added and the fluorescence continued to increase
proportionally to the number of cells (Fig. 3c, f ). In both
measurements (when pp65-specific or TARP-specific
T-cells were used) the fluorescence maximum was
three times higher with three times higher cell
amount (Fig. 3d, g). There was a bigger variation in the
slope when additional cells were added compared to the
initial binding curves (Fig. 3e, h). This could be due to the
nature of the process of binding, which is accompanied
with killing of target cells that would eventually lead to de-
tachment of the effector cells. The rate of detachment
would depend on the particular speed of apoptosis in-
duced in the individual cells and this may vary.
Fig. 1 Lentiviral vector for expression of recombinant TCRs. A self-inactivating lentiviral vector was constructed with recombinant TCR α and β
chains with human variable (V), diversity (D) and joining (J) gene segments and mouse constant (C) domains. The TCR α and β chains are sepa-
rated by a self-cleaving T2A peptide and the SFFV promoter controls TCR expression. Lentivirus particles were produced in 293 T-cells and con-
centrated by ultracentrifugation before being used to transduce human T-cells. Abbreviations: TCR = T-cell receptor; LTR = long terminal repeat;
SIN = self inactivating (deletion of the direct repeat enhancer); SSFV = spleen-focus forming virus; V = variable, D = diversity and J = joining gene
segment; T2A = 2A peptide derived from Thosea asigna virus
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T-cells engineered to recognize the foreign CMV pp65
antigen kill target cells more efficiently than T-cells
engineered to recognize the self-antigen TARP
To compare the differences in functional avidity, the
performance of the TCR-engineered T-cells was studied
in effector functional assays. In the interferon (IFN)-γ
assays, the pp65-specific T-cells were superior to the
TARP-specific T-cells (Fig. 4a). They required lower pep-
tide amount concentrations (about 1 nanomolar) in
order to be activated and produce IFN-γ, in contrast to
TARP-specific T-cells, which required a minimum of
100 nM peptide to produce significant amount of IFN-γ
(Fig. 4b). Cytokine production is an important effector
function, but it does not directly measure the ability of
the cytotoxic T-cells to kill target cells. In some cases,
primarily in the setting of virus-specific T-cells, IFN-γ
producing cells may fail to exert a potent cytotoxic func-
tion [22–24]. To further analyze the ability of the TCR-
engineered T-cells to respond to antigen stimulation, the
pp65-TCR and TARP-TCR T-cells were compared in
killing assays using luciferase-tagged target cells. We hy-
pothesized that more functionally effective T-cells would
respond to smaller antigen doses, and it also would take
less number of effector cells to neutralize the same num-
ber of target cells. TARP-specific T-cells killed efficiently
their targets at 10 μM peptide (Fig. 4c), and at effector
to target ratios of 5:1 when the highest peptide
concentration was used (Fig. 4d). In contrast, the pp65-
specific T-cells started to exert their cytotoxic function
already at 100 pM and efficient killing was achieved at
peptide concentration of 10 nM (Fig. 4c). Furthermore,
at effector to target ratio of 1:5, approximately half of
the target cells underwent apoptosis. Both TCRs were ef-
fective at high concentrations of peptide.
To monitor target cell killing in real time, we used the
xCELLigence technology, which measures cell growth
and proliferation through electrical impedance measure-
ments. In this assay, impedance was measured every
15 min for a total of 72 h. By measuring the growth of
peptide-pulsed mel526 target cells in presence of T-cells,
the T-cell cytotoxicity was estimated. The mel526 cell
growth was measured for 24 h before TCR-engineered
T-cells were added and then measured for an additional
48 h. TARP-TCR T-cells killed their targets less efficient
and slower than pp65-TCR T-cells. We observed a re-
sponse in relation to the amount of peptide added for
both pp65-TCR T-cells and TARP-TCR T-cells (Fig. 5a).
When target cells were pulsed with 10 μM peptide and
effector cells were added at different effector to target
ratio, a T-cell dose-dependent response was observed
(Fig. 5b). That was more apparent for the TARP-TCR T-
cells where there was an improvement of killing with T-
cell dose, whereas for pp65-TCR T-cells there was
improvement of response when increasing the effector
Fig. 2 Analysis of TCR-engineered T-cells. Human T-cells in a PBMC pool from healthy volunteers were activated and transduced with the pp65-
TCR and TARP-TCR, respectively. The CD3+ T-cells were then evaluated for TCR expression by flow cytometry using multimer technologies and
CD8 and CD4 staining. Expression of the transferred TCR was assessed seven days after lentiviral transduction (a), after multimer-guided magnetic
bead sorting (b) and after an additional fourteen days of rapid expansion (c). The T-cells where analyzed after expansion in terms of percent TCR
positive T-cells (d) and mean fluorescent intensity (e). SSC = side scatter
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to target cell ratio from 1:1 to 5:1, but at effector to tar-
get ratio 5:1 the T-cell response was already saturated
(Fig. 5b). A magnification of T-cell killing during the
first four hours are shown in Fig. 5c.
Discussion
We have previously identified a novel TCR against an
HLA-A2-restricted peptide from the prostate and breast
cancer-associated antigen TARP [13] and in this study,
we have further characterized its interaction and binding
to HLA-A2+ targets cells. We also report the cloning of
a TCR against an HLA-A2-restricted peptide from CMV
pp65 and demonstrate its strong ability to recognize and
kill pp65-pulsed HLA-A2+ target cells. The purpose of
this study was to investigate the difference in target rec-
ognition between T-cells with a virus-directed TCR
(pp65-specific) and tumor self antigen-directed TCR
(TARP-specific) using both established and novel ana-
lyses methods.
It is known that high and low affinity TCRs needs differ-
ent peptide concentrations to exert cytotoxicity and we pre-
dicted that to be the case for the pp65-specific and TARP-
specific TCRs. From our functional in vitro studies (IFN-γ
release and cytotoxicity) it is clear that T-cells with the
pp65-specific TCR respond to a lower peptide concentra-
tion than T-cells with the TARP-specific TCR. We verified
that pp65-TCR T-cells were also able to kill target cells at
low peptide concentration (100 pM) as previously described
for T-cells specific to a different antigen [25, 26]. The bio-
informatics predictive value of the binding strength of the
peptide to HLA-A2, as estimated by NetMHC was compar-
able for the TARP(P5L)4–13 or pp65495–503 peptides. Both
were categorized as strong binders. Therefore, we believe
that a direct comparison between the two TCRs is valid.
Fig. 3 Real time analysis of TCR T-cell binding to peptide-presenting target cells. LigandTracer® (a) was used to assess the binding of pp65-TCR
and TARP-TCR-engineered human T-cells to HLA-A2 positive target cells (mel526) presenting the cognate peptide (b). Target cells were adhered
over-night to one side of a Petri dish and then pulsed with either TARP4–13 (10 μM] or pp65495–503 (10 nM). Sorted and expanded pp65-TCR and
TARP-TCR-engineered T-cells were labeled with CFSE and washed before being added to the dish with peptide-pulsed target cells. Binding of
TCR-engineered T-cells to peptide-pulsed target cells was measured in real time for 90 min using 1.5 × 105 T-cells and an additional 90 min using
4.5 × 105. Binding kinetics in terms of fluorescence signal from target cells is shown for pp65-TCR T-cells (c), with proportional increase of signal
when three times more T-cells were added (d), and representation of the binding slope (e). Binding kinetics in terms of fluorescence signal from
target cells is shown for TARP-TCR T-cells (f), with proportional increase of signal when three times more T-cells were added (g), and representation of
the binding slope (h)
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When using multimers to assess the TCRs we found
that the pp65-TCR resulted in a higher transduction rate
(%-wise) of T-cells and that the T-cells had higher MFI
than the TARP-TCR. There were slightly more CD4+ T-
cells than CD8+ T-cells that were multimer positive for
both TCRs. The reason for this is unknown but it may
indicate a slight preference of transducing CD4+ T-cells
over CD8+ T-cells, that CD4+ T-cells have better viabil-
ity after transduction with lentiviral vectors or simply
this occurs because there are more CD4+ T-cells than
CD8+ T-cells in peripheral blood. CD8+ T-cells had a
higher MFI than CD4+ T-cells. This is expected as the
transferred TCRs interact with HLA-A2 (MHC class I)
for which CD8 is the co-receptor. The fact that CD4+ T-
cells could also be detected by multimers indicates that
both TCRs had a rather high affinity since they could be
detected without the CD8 co-receptor. In the thera-
peutic setting of adoptive T-cell transfer it may be ad-
vantageous to have T-cells that have a good binding for
the target antigen but do not get activated too rapidly, as
that may lead to their exhaustion.
When using IFN-γ release and in vitro killing assays
pp65-TCR T-cells were superior to TARP-TCR T-cells.
This is probably due to higher affinity. TARP is a self-
antigen and the TARP-TCR was cloned from a healthy
HLA-A2 positive donor [13]. Although TARP has re-
stricted expression in differentiated cells it is possible
that the TARP4–13 epitope has been presented by thymic
antigen-presenting cells during T-cell development and
the high affinity T-cell clones against it were deleted
during negative selection. Most T-cells recognizing self-
antigens (including tumor-associated self antigens) are
of lower affinity and avidity or anergic. A recent study,
addressing the responses of several TCRs directed
against tumor-associated antigens, concludes that T2
cells pulsed with nanomolar concentrations of peptide
generally corresponds to the number of epitopes that are
physiologically presented by tumor cells [27]. For the
TCRs tested in that study, partial response was detected
at 10 nM peptide for all antigens tested in terms of ELI-
SPOT IFN-γ production [27]. Although it is difficult to
directly compare our results with theirs, small amounts
of IFN-γ were detected in our study at 10 nM TARP
peptide by ELISA. Of note, the amounts detected
exceeded the limit for reactive clones that is used in
adoptive T-cell transfer of expanded tumor-infiltrating
lymphocytes to cancer patients of some investigators
[28]. One also need to keep in mind that T-cells with a
high affinity TCR have caused severe side effects in ex-
perimental treatment of cancer with adoptively trans-
ferred T-cells [29]. One suggested mechanism is through
TCR signaling enhancement through Tim-3 [30].
In this study, we introduce LigandTracer technology
as a method to monitor the binding of T-cells to target
cells in real time. It is a convenient method to demon-
strate the increase in the binding as the signal is propor-
tional to the number of the cells and increases in a
linear fashion. TCR binding to the cognate peptide was
Fig. 4 pp65-TCR and TARP-TCR-engineered T-cells show therapeutic effect when encountering HLA-A2 positive target cells presenting the cognate
peptide. Sorted and expanded pp65-TCR and TARP-TCR-engineered human T-cells were assayed for response in IFN-γ production (a, magnified in b)
and killing (c) of HLA-A2+ mel526 target cells pulsed with a range of peptide concentrations. Inactivation of target cells was also assayed at various
effector to target cell ratios with target cells pulsed with 10 μM peptide (d)
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demonstrated both for the TARP-TCR and pp65-TCR
but peptide concentration on target cells needs to be
adjusted for individual TCRs for optimal result. It is
therefore difficult to directly compare the pp65-specific
T-cells and the TARP-specific T-cells. However, Ligand-
Tracer data suggest that the better in vitro performance
of the pp65-TCR T-cells (IFN-γ release and cytotoxicity)
cannot be explained solely with better binding to target
cells. To complement the binding data from the Ligand-
Tracer experiments, we looked at target cell inactivation
in real time using the xCELLigence cell growth assay
technology to assess the killing potency of the TCR-
engineered T-cells. The TARP-TCR T-cells were less effi-
cient in killing their targets and required both higher
peptide concentrations and higher effector to target
ratios to achieve efficient response. The killing kinetics
differed between the TARP-TCR T-cells and pp65-TCR
T-cells, and it may indicate that there are different
mechanisms that are employed if the T-cell-mediated
killing is slower. The TARP-TCR T-cells were able to kill
target cells, which growth plateaued at Cell Index of ap-
proximately 1, whereas pp65-TCR T-cells had fast and
efficient killing shown by the Cell Index going back to 0.
For TARP-TCR T-cells, at all peptide concentrations,
Fig. 5 Target cell death in response to pp65-TCR and TARP-TCR-engineered T-cells in real time. Mel526 target cells were plated in E-Plate View
and continuously monitored for growth using the xCELLigence DP Instrument for approximately 24 h. a The mel526 target cells in the E-Plate
View were then pulsed with pp65495–503 peptide at 10 μM (Slateblue), 100 nM (Coral) or 1nM (Cyan), or TARP4–13 peptide at 10 μM (Magenta),
100 nM (Green) or 1 nM (Blue), or irrelevant VMAT-131–39 peptide as a control (Saddlebrown) for 2 h. The pp65-TCR or TARP-TCR-engineered
T-cells were then added at effector to target cell ratio of 5:1. The Cell Index measured was normalized to the time point of T-cell addition. Arrows
indicate peptide and T-cell addition. b The mel526 target cells in the E-Plate View were pulsed with pp65495–503 and TARP4–13 peptide at 10 μM
for 2 h. pp65-TCR T-cells were then added in effector to target ratios 1:1 (Cyan), 5:1 (Coral) or 10:1 (Slateblue) or TARP-TCR T-cells were added at
ratios 1:1 (Green), 5:1 (Blue) or 10:1 (Magenta), or no T-cells were added as a control (Saddlebrown). Arrows indicate peptide and T-cell addition.
c Growth curves between 26 and 30 h of measurement, i.e., 0 to 4 h post addition of T-cells, are magnified from A (Left) and B (right)
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and for pp65-TCR T-cells, at a low peptide concentra-
tion, targets cells started to grow back again, but were
then killed in something that looks like a second wave of
T-cell killing. In the case of pp65-TCR T-cells, after the
re-growth of target cells, T-cells took control again and
the Cell Index dropped to 0. Taken together the data in-
dicate a more rapid and efficient response of pp65-TCR
T-cells, and that dependent on the TCR the T-cells may
need more time to kill their target cells. It is also pos-
sible that because of different binding avidity the target
cells could undergo apoptosis at a different speed. Be-
cause of the real time fine resolution of the xCELLigence
assay (Fig. 5c) and possibility to long term follow up
(Fig. 5a, b) we suggest that this assay can efficiently re-
place the standard 51Cr-release assay for T-cell mediated
killing.
Conclusions
This paper includes new assays for T-cell binding to tar-
get cells and T-cell killing of target cells that can become
useful tools to study the kinetics of T-cell mediated kill-
ing. The pp65-TCR cloned in this paper has high affinity
and T-cells engineered with this TCR can efficiently kill
target cells, indicating that the pp65-TCR may be used
to produce T-cells to treat CMV reactivation after trans-
plantation in HLA-A2 recipients. Previous data pub-
lished by us [13] together with data presented in this
paper indicate that the TARP-TCR may have an appro-
priate affinity for TCR-based T-cell immunotherapy.
TARP-directed T-cells bound their targets well but had
a less potent effector function than pp65-directed T-
cells. Further in vivo experiments may elucidate the
physiological strength of its effector function and deter-
mine whether affinity enhancement of the TCR would
be necessary in order to achieve a better cytotoxic re-
sponse without compromising its specificity.
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